The Hyperthermia Treatment for Cancer Market to prove to be the digitized mouthpiece at a CAGR of 6.1%

The Hyperthermia Treatment for Cancer Market is there to witness a placid CAGR of 6.1% between 2017-2025, reaching US$ 160 Mn. Telehealth has turned out to be a boon – be it with remote monitoring or treating several patients at a distance simultaneously. The time as well stresses on the part of patients and physicians gets saved this way. Virtual follow-up also opens doors for multitasking by the healthcare personnel. This is the present and also would be the future of the healthcare vertical.

The increasing number of cancer patient worldwide is translating into higher demand for cancer therapies. Governments in various countries have launched promotional campaigns to aware people about getting the right cancer treatment. To an extent, these aforementioned factors are helping popularize various cancer therapeutics including hyperthermia treatment for cancer. Moreover, medical institutes are working in collaboration with the government for cancer research to further improve diagnosis and treatment.

Get a Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14632

Clinical trials are also funded by governments to support companies in developing effective hyperthermia treatments for cancer. Persistence Market Research (PMR) in its latest report titled “Hyperthermia Treatment for Cancer Market: Global Industry Analysis and Forecast, 2017–2025” projects that global hyperthermia treatment for cancer market revenue will surge at a CAGR of 6.1% during the forecast period (2017–2025).

Company Profiles:

• Celsius42+ GmbH
• Pyrexar Medical Inc.
• Oncothermia
• Hydrosun GmbH
• Yamamoto Vinita Co., Ltd
• Andromedic Srl
• Haifu Medical Technology Co. Ltd

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/14632

Global Hyperthermia Treatment for Cancer Market – Key Highlights 

• By device type, the microwave hyperthermia device segment is estimated to account for 41.4% revenue share of the market by 2017-end. The segment is expected to further gain traction, owing to its ability to transmit energy from antenna to cancer cells without getting stuck in fat layers. Meanwhile, short-wave hyperthermia device segment is expected to witness the fastest CAGR of 7.0% during the forecast period.
• Based on application, breast cancer and leukemia segments collectively accounted for 45% of the total market in 2016 and is expected to remain as the two dominant application segments of the market in 2017 and beyond.
• By end use, the hospitals end user segment accounted for more than 42% share of the market. This is primarily owing to the growing ration of cancer patients in hospitals.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/14632

Among regions, the market for hyperthermia treatment for cancer in North America is expected to remain dominant throughout the forecast. In 2016, the region’s market reached a valuation of US$ 39.4 Mn and anticipated to grow at a CAGR of 5.5% over the projection period. This is majorly attributed to the presence of leading medical companies and healthcare organizations in the region. Meanwhile, the market in Asia-Pacific is set to witness the fastest CAGR of 7.2%. By the 2017-end, the region is projected to account for 10.0% revenue share of the market.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com